200 related articles for article (PubMed ID: 21394020)
1. Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.
Ravaud A; Bello CL
Anticancer Drugs; 2011 Jun; 22(5):377-83. PubMed ID: 21394020
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
4. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
Castellano D; Ravaud A; Schmidinger M; De Velasco G; Vazquez F
Cancer Treat Rev; 2013 May; 39(3):230-40. PubMed ID: 22647546
[TBL] [Abstract][Full Text] [Related]
5. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
6. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of sunitinib in hemodialysis.
Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
[No Abstract] [Full Text] [Related]
9. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Castellano D; Maroto JP; Espinosa E; Grande E; Bolós MV; Llinares J; Esteban E; González Del Alba A; Climent MA; Arranz JA; Méndez MJ; Fernández Parra E; Antón-Aparicio L; Bayona C; Gallegos I; Gallardo E; Samaniego L; García Donas J
Expert Opin Drug Saf; 2018 Jun; 17(6):573-579. PubMed ID: 28535693
[TBL] [Abstract][Full Text] [Related]
10. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
13. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Kruse V; Somers A; Van Bortel L; De Both A; Van Belle S; Rottey S
J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Ezz El Din M
Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
